Helpline 800-723-9166
Donate
Advance Online
Advance Online

FDA Approves Skyrizi for Plaque Psoriasis

The latest interleukin-23 inhibitor is aimed at adults with moderate-to-severe psoriatic disease.

April 24, 2019
Recent Advance ArticlesNPF Logo
A Heartbreaking (and Relatable) Holiday Wish

Stay in the Know

Expert tips, can’t-miss events, and the latest news, straight to your inbox.

National Health Council Standards of ExcellenceCharity NavigatorCommunity Health Charities logo

Copyright © 1996-2024 National Psoriasis Foundation/USA


The National Psoriasis Foundation is a qualified 501(c)(3) EIN 93-0571472.


Duplication, rebroadcast, republication, or other use of content appearing on this website is prohibited without written permission of the National Psoriasis Foundation (NPF).


NPF does not endorse or accept any responsibility for the content of external websites.


NPF does not endorse any specific treatments or medications for psoriasis and psoriatic arthritis.

We use cookies to offer you a better experience and analyze our site traffic. By continuing to use this website, you consent to the use of cookies in accordance with our Privacy Policy.